Percutaneous treatment of paravalvular leaks after transcatheter aortic valve implantation with the CoreValve self-expanding bioprosthesis

Mild-to-moderate aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) is common and often clinically silent. Higher-degree AR may occur, with significant haemodynamic and clinical consequences. Treatment of this condition is challenging and there are no evidence-based therapeutic options. This image illustrates the successful percutaneous management of clinically relevant paravalvular leaks (PVL) after implantation of the CoreValve bioprosthesis (Medtronic, Minneapolis, MN, USA) with the use of vascular plug devices.

Conflict of interest statement

The authors report no financial relationships or conflicts of interest regarding the content herein.



Figure 1. Examples of successful percutaneous closure of severe paravalvular ...